Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis

Zheng, Jiachun; Qin, Chuling; Wang, Qianxi; Tian, Dongbo; Chen, Zisheng

doi:10.1016/j.ebiom.2024.105109

eBioMedicine

2024

DOI: 10.1016/j.ebiom.2024.105109

|View full text |Cite

Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis

Jiachun Zheng,

Chuling Qin,

Qianxi Wang

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

CRISPR/Cas12a Corona Nanomachine for Detecting Circulating Tumor Nucleic Acids in Serum

Yuan,

Sun,

Chen

et al. 2024

Anal. Chem.

View full text Add to dashboard Cite

Circulating tumor nucleic acids (CTNAs), which consist of cell-free DNA or RNA released from tumor cells, are utilized as potential biomarkers for diagnosing and managing tumor prognosis. There is a significant demand for developing a highly sensitive and reliable assay for CTNAs detection. In this study, we engineered a CRISPR/Cas12a corona nanomachine capable of detecting circulating tumor DNA and RNA in serum. This nanomachine consists of a protein shell incorporating Cas12a/ crRNA ribonucleoprotein complexes and a scaffold AuNP core decorated with substrate ssDNA strands. The protective CRISPR corona shields the nucleic acid core from degradation by nuclease DNase/RNase, thereby enhancing the stability of the CRISPR/ Cas12a corona nanomachine in biological fluids, even tolerating up to undiluted human serum and FBS. Upon encountering target CTNAs, the CRISPR/Cas12a is activated through the sequence-specific hybridization between crRNA and CTNAs. Subsequently, the activated CRISPR/Cas12a autonomously cleaves the collateral ssDNA substrates on AuNPs, releasing the fluorophore-labeled fragment and generating an increasing fluorescent signal. The CRISPR corona nanomachine was successfully employed to detect various CTNAs, including circulating tumor (ct)DNA/RNA (EGFR L858R) and microRNA-21, achieving a limit of detection of 0.14 pM for ctDNA and 1.0 pM for RNA. This CRISPR corona nanomachine enables simultaneous detection of both DNA and RNA in complex biological samples, offering a promising tool for early diagnosis.

show abstract

CRISPR/Cas12a Corona Nanomachine for Detecting Circulating Tumor Nucleic Acids in Serum

Yuan,

Sun,

Chen

et al. 2024

Anal. Chem.

View full text Add to dashboard Cite

show abstract

Minimal residual disease as a target for liquid biopsy in patients with solid tumours

Pantel,

Alix-Panabières

2024

Nat Rev Clin Oncol

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis

Cited by 2 publications

References 105 publications

CRISPR/Cas12a Corona Nanomachine for Detecting Circulating Tumor Nucleic Acids in Serum

CRISPR/Cas12a Corona Nanomachine for Detecting Circulating Tumor Nucleic Acids in Serum

Minimal residual disease as a target for liquid biopsy in patients with solid tumours

Contact Info

Product

Resources

About